Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient

Clinical Nephrology

Volumn 54, Issue 5, 2000, Pages 418-424

  Ketteler, M ^a   Preuschof, L ^a   Mertz, A ^a   Stoffler Meilicke, M ^a   Schafer, H ^a   Distler, A ^a   Offermann, G ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Antiviraltherapy; Cytomegalovirus; Pneumonia; Preemptive; Renal transplant recipient

Indexed keywords

CIDOFOVIR; FOSCARNET SODIUM; GANCICLOVIR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BIOASSAY; CASE REPORT; CAUSE OF DEATH; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RATE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUNG BIOPSY; MORTALITY; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; RESPIRATORY FAILURE; THORACOTOMY; TREATMENT OUTCOME; VIRUS PNEUMONIA;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; FATAL OUTCOME; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PNEUMONIA, VIRAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS;

EID: 0033762308     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS
2. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up
3. Quantitation of cytomegalo-virus: Methodologic aspects and clinical applications
4. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
5. The prevention of cytomegalovirus disease in renal transplantation
6. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification
7. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT
8. Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation
9. Cidofovir in the treatment of cytomegaloviral disease
10. Detection of cytomegalovirus by in situ hybridisation and immunohistochemistry using new monoclonal antibody CCH2: A comparison of methods
11. Diagnosis of cytomegalovirus (CMV) disease in renal allograft recipients: The role of semiquantitative polymerase chain reaction (PCR)
12. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients
13. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation